Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04776148
Registration number
NCT04776148
Ethics application status
Date submitted
26/02/2021
Date registered
1/03/2021
Titles & IDs
Public title
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
Query!
Scientific title
A Phase 3 Randomized Study of Lenvatinib in Combination With Pembrolizumab Versus Standard of Care in Participants With Metastatic Colorectal Cancer Who Have Received and Progressed On or After or Became Intolerant to Prior Treatment
Query!
Secondary ID [1]
0
0
MK-7902-017
Query!
Secondary ID [2]
0
0
7902-017
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Colorectal Neoplasms
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Bowel - Back passage (rectum) or large bowel (colon)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - pembrolizumab
Treatment: Drugs - lenvatinib
Treatment: Drugs - regorafenib
Treatment: Drugs - TAS-102 (trifluridine and tipiracil)
Experimental: lenvatinib+pembrolizumab - Participants receive pembrolizumab 400 mg via intravenous (IV) infusion on Day 1 of each 6-week (Q6W) Cycle for up to 18 cycles (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule once daily until progressive disease.
Active comparator: standard of care treatment (regorafenib OR TAS-102) - Participants receive regorafenib 160 mg via oral tablet once daily on Days 1 through 21 of each 4-week cycle OR TAS-102 (trifluridine and tipiracil hydrochloride) 35 mg/m\^2 via oral tablet twice a day on Days 1 through 5 and Days 8-12 of each 4-week cycle until progressive disease.
Treatment: Drugs: pembrolizumab
IV infusion
Treatment: Drugs: lenvatinib
oral capsule
Treatment: Drugs: regorafenib
oral tablet
Treatment: Drugs: TAS-102 (trifluridine and tipiracil)
oral tablet
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS was defined as the time from randomization to the date of death from any cause.
Query!
Timepoint [1]
0
0
Up to approximately 22 months
Query!
Secondary outcome [1]
0
0
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Query!
Assessment method [1]
0
0
PFS was defined as the time from date of randomization to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD was defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of =5 mm. Note: The appearance of one or more new lesions was also considered PD. PFS as assessed by BICR per modified RECIST 1.1 is presented.
Query!
Timepoint [1]
0
0
Up to approximately 22 months
Query!
Secondary outcome [2]
0
0
Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR
Query!
Assessment method [2]
0
0
ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. ORR per modified RECIST 1.1 assessed by BICR is presented.
Query!
Timepoint [2]
0
0
Up to approximately 22 months
Query!
Secondary outcome [3]
0
0
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR
Query!
Assessment method [3]
0
0
For participants who demonstrated CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), DOR is defined as the time from the first documented evidence of CR or PR until PD or death from any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, or death from any cause, PD is defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of =5 mm. Note: The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR per modified RECIST 1.1 is presented.
Query!
Timepoint [3]
0
0
Up to approximately 22 months
Query!
Secondary outcome [4]
0
0
Number of Participants Who Experience an Adverse Event (AE)
Query!
Assessment method [4]
0
0
An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Query!
Timepoint [4]
0
0
Up to approximately 22 months
Query!
Secondary outcome [5]
0
0
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
Query!
Assessment method [5]
0
0
An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued any study treatment due to an adverse event is presented.
Query!
Timepoint [5]
0
0
Up to approximately 22 months
Query!
Secondary outcome [6]
0
0
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Query!
Assessment method [6]
0
0
The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to the questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and Quality of Life (QoL; "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in GHS (EORTC QLQ-C30 Item 29) and QoL (EORTC QLQ-C30 Item 30) combined score will be presented. A higher score indicates a better outcome.
Query!
Timepoint [6]
0
0
Baseline and 8 weeks
Query!
Secondary outcome [7]
0
0
Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score
Query!
Assessment method [7]
0
0
The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 5 questions about their physical functioning (Items 1-5) are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. Higher scores meant a better level of function.
Query!
Timepoint [7]
0
0
Baseline and 8 weeks
Query!
Secondary outcome [8]
0
0
Change From Baseline in EORTC QLQ-C30 Appetite Loss (Item 13) Score
Query!
Assessment method [8]
0
0
The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire, including a single-item scale score for appetite loss (QLQ-C30 Item 13). For this item, individual responses to the question "Have you lacked appetite?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-C30 appetite loss (Item 13) scale score is presented.
Query!
Timepoint [8]
0
0
Baseline and 8 weeks
Query!
Secondary outcome [9]
0
0
Change From Baseline in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score
Query!
Assessment method [9]
0
0
The EORTC QLQ-CR29 is a health-related quality-of life (QoL) questionnaire specific for colorectal cancer, including a single-item scale score for bloating (QLQ-CR29 Item 37). For this item, individual responses to the question "Did you have a bloated feeling in your abdomen?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-CR29 bloating (Item 37) scale score is presented.
Query!
Timepoint [9]
0
0
Baseline and 8 weeks
Query!
Secondary outcome [10]
0
0
Time to Deterioration (TTD) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Query!
Assessment method [10]
0
0
TTD is defined as the time from baseline to the first onset of a =10-point deterioration (decrease) from baseline in Global Health Status (GHS; EORTC QLQ-C30 Item 29) \& Quality of Life (QoL; EORTC QLQ-C30 Item 30) combined score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a =10-point negative change (decrease) from baseline in GHS and QoL combined score, is presented. A longer TTD indicates a better outcome.
Query!
Timepoint [10]
0
0
Up to approximately 21 months
Query!
Secondary outcome [11]
0
0
TTD in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score
Query!
Assessment method [11]
0
0
TTD is defined as the time from baseline to the first onset of a =10-point deterioration (decrease) from baseline in physical functioning score (QLQ-C30 Items 1-5). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a =10-point negative change (decrease) from baseline in physical functioning score, is presented. A longer TTD indicates a better outcome.
Query!
Timepoint [11]
0
0
Up to approximately 21 months
Query!
Secondary outcome [12]
0
0
TTD in EORTC QLQ-C30 Appetite Loss (Item 13) Score
Query!
Assessment method [12]
0
0
TTD is defined as the time from baseline to the first onset of a =10-point deterioration (increase) from baseline in appetite loss (QLQ-C30 Item 13) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a =10-point change (increase) from baseline in appetite loss score, is presented. A longer TTD indicates a better outcome.
Query!
Timepoint [12]
0
0
Up to approximately 21 months
Query!
Secondary outcome [13]
0
0
TTD in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score
Query!
Assessment method [13]
0
0
TTD is defined as the time from baseline to the first onset of a =10-point deterioration (increase) from baseline in bloating (QLQ-CR29 Item 37) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a =10-point change (increase) from baseline in appetite loss score, is presented. A longer TTD indicates a better outcome.
Query!
Timepoint [13]
0
0
Up to approximately 21 months
Query!
Eligibility
Key inclusion criteria
* Has histologically or cytologically confirmed diagnosis of unresectable and metastatic colorectal adenocarcinoma (Stage IV A, B and C as defined by American Joint Committee on Cancer [AJCC] 8th edition). Note: Tumor must be determined to be NOT microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) by local testing
* Has been previously treated for their disease and has shown disease progression as defined by RECIST 1.1 on or after or could not tolerate standard treatment, which must include ALL of the following agents if approved and locally available in the country where the participant is randomized:
1. fluoropyrimidine, irinotecan and oxaliplatin
2. with or without an anti-vascular endothelial growth factor (VEGF) monoclonal antibody (bevacizumab)
3. with anti- epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab or panitumumab) for RAS (KRAS/NRAS) wild-type (WT) participants
4. BRAF inhibitor (in combination with cetuximab +/- binimetinib) for BRAF V600E mutated metastatic colon cancer (mCRC)
* Has measurable disease per RECIST 1.1 assessed by the investigator
* Has provided to a designated central laboratory an archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion which has not been previously irradiated
* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 3 days prior to randomization
* Has a life expectancy of at least 3 months, based on the investigator assessment
* Has the ability to swallow capsules or ingest a suspension orally or by a feeding tube
* Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP =150/90 millimeter of mercury (mmHg) with no change in antihypertensive medications within 1 week prior to randomization
* Male participants must agree to the following during the treatment period and for at least 90 days after the last dose of regorafenib or TAS-102 and at least 7 days after the last dose of lenvatinib: refrain from donating sperm PLUS either be abstinent from heterosexual intercourse as their preferred and usual lifestyle or use contraception. The male contraception period should continue for at least 7 days after discontinuation of lenvatinib
* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of childbearing potential (WOCBP) OR is a WOCBP and using a highly-effective contraceptive method during the treatment period and for at least 30 days after the last dose of lenvatinib, 120 days after the last dose of pembrolizumab, and 180 days after the last dose of regorafenib or TAS-102 (whichever is last) AND agrees not to donate eggs (ova, oocytes)
* A WOCBP must have a negative highly sensitive pregnancy test (urine or serum) within 24 hours before the first dose of study treatment
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Has a tumor that is microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) per local testing
* Has presence of gastrointestinal condition, eg, malabsorption, that might affect the absorption of study drug.
* Has present or progressive accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment
* Has radiographic evidence of encasement or invasion of a major blood vessel invasion or of intratumoral cavitation. In the chest, major blood vessels include the main pulmonary artery, the left and right pulmonary arteries, the 4 major pulmonary veins, the superior or inferior vena cava, and the aorta
* Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug
* Has clinically significant cardiovascular disease within 12 months from first dose of study intervention, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability.
Participants with cardiac failure NYHA Class II, III and IV are not allowed to be assigned to the regorafenib in Arm B
* Has a history of arterial thromboembolism within 12 months of start of study drug
* Has urine protein =1 gram/24 hour
* Has prolongation of QT interval corrected with Fridericia's formula (QTcF interval) to >480 milliseconds
* Has left ventricular ejection fraction (LVEF) below the institutional (or local laboratory) normal range as determined by multigated acquisition (MUGA) or echocardiogram (ECHO)
* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years with certain exceptions
* Has serious nonhealing wound, ulcer or bone fracture
* Has had major surgery within 3 weeks prior to first dose of study treatment
* Has received biologic response modifiers (eg, granulocyte colony-stimulating factor) within 4 weeks before study entry
* Has preexisting =Grade 3 gastrointestinal or nongastrointestinal fistula
* Has received prior treatment with a combination of an anti-PD-1, anti-PD-L1, or anti PD-L2 agent with anti-VEGF monoclonal antibodies or vascular endothelial growth factor receptor (VEGFR) inhibitors
* Has previously received regorafenib or TAS-102
* Has received prior systemic anti-cancer therapy including investigational agents within 28 days prior to randomization
* Has received prior radiotherapy within 2 weeks of start of study treatment
* Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study treatment
* Has known intolerance to lenvatinib, regorafenib, or TAS-102 and/or any of their excipients
* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 28 days prior to the first dose of study treatment
* Has known central nervous system (CNS) metastases and/or carcinomatous meningitis.
* Has severe hypersensitivity (=Grade 3) to pembrolizumab and/or any of its excipients
* Has an active autoimmune disease that has required systemic treatment in past 2 years
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication
* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
* Has an active infection requiring systemic therapy
* Has a known history of Human Immunodeficiency Virus (HIV) infection
* Has a known history of Hepatitis B or known active Hepatitis C virus infection
* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
* Has had an allogenic tissue/solid organ transplant
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
29/03/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
27/09/2024
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
480
Query!
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si - Brisbane
Query!
Recruitment hospital [2]
0
0
Gallipoli Medical Research Foundation-GMRF CTU ( Site 1500) - Greenslopes
Query!
Recruitment hospital [3]
0
0
The Queen Elizabeth Hospital-Cancer Clinical Trials ( Site 1503) - Woodville
Query!
Recruitment hospital [4]
0
0
Epworth Freemasons ( Site 1506) - Melbourne
Query!
Recruitment hospital [5]
0
0
Western Health-Sunshine & Footscray Hospitals ( Site 1501) - St Albans
Query!
Recruitment hospital [6]
0
0
Hollywood Private Hospital-Medical Oncology ( Site 1507) - Perth
Query!
Recruitment postcode(s) [1]
0
0
4029 - Brisbane
Query!
Recruitment postcode(s) [2]
0
0
4120 - Greenslopes
Query!
Recruitment postcode(s) [3]
0
0
5011 - Woodville
Query!
Recruitment postcode(s) [4]
0
0
3002 - Melbourne
Query!
Recruitment postcode(s) [5]
0
0
3021 - St Albans
Query!
Recruitment postcode(s) [6]
0
0
6009 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Georgia
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Illinois
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Maryland
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Michigan
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Montana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Oregon
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Pennsylvania
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Virginia
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Washington
Query!
Country [11]
0
0
Argentina
Query!
State/province [11]
0
0
Buenos Aires
Query!
Country [12]
0
0
Argentina
Query!
State/province [12]
0
0
Caba
Query!
Country [13]
0
0
Argentina
Query!
State/province [13]
0
0
Santa Fe
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
Alberta
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Nova Scotia
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Ontario
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Quebec
Query!
Country [18]
0
0
China
Query!
State/province [18]
0
0
Guangdong
Query!
Country [19]
0
0
China
Query!
State/province [19]
0
0
Zhejiang
Query!
Country [20]
0
0
Denmark
Query!
State/province [20]
0
0
Hovedstaden
Query!
Country [21]
0
0
Denmark
Query!
State/province [21]
0
0
Syddanmark
Query!
Country [22]
0
0
Germany
Query!
State/province [22]
0
0
Baden-Wurttemberg
Query!
Country [23]
0
0
Germany
Query!
State/province [23]
0
0
Bayern
Query!
Country [24]
0
0
Germany
Query!
State/province [24]
0
0
Nordrhein-Westfalen
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
Berlin
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Hamburg
Query!
Country [27]
0
0
Israel
Query!
State/province [27]
0
0
Haifa
Query!
Country [28]
0
0
Israel
Query!
State/province [28]
0
0
Jerusalem
Query!
Country [29]
0
0
Israel
Query!
State/province [29]
0
0
Ramat Gan
Query!
Country [30]
0
0
Israel
Query!
State/province [30]
0
0
Tel Aviv
Query!
Country [31]
0
0
Japan
Query!
State/province [31]
0
0
Aichi
Query!
Country [32]
0
0
Japan
Query!
State/province [32]
0
0
Chiba
Query!
Country [33]
0
0
Japan
Query!
State/province [33]
0
0
Hyogo
Query!
Country [34]
0
0
Japan
Query!
State/province [34]
0
0
Kagawa
Query!
Country [35]
0
0
Japan
Query!
State/province [35]
0
0
Kanagawa
Query!
Country [36]
0
0
Japan
Query!
State/province [36]
0
0
Osaka
Query!
Country [37]
0
0
Japan
Query!
State/province [37]
0
0
Saitama
Query!
Country [38]
0
0
Japan
Query!
State/province [38]
0
0
Shizuoka
Query!
Country [39]
0
0
Japan
Query!
State/province [39]
0
0
Fukuoka
Query!
Country [40]
0
0
Japan
Query!
State/province [40]
0
0
Tokyo
Query!
Country [41]
0
0
Korea, Republic of
Query!
State/province [41]
0
0
Seoul
Query!
Country [42]
0
0
Russian Federation
Query!
State/province [42]
0
0
Baskortostan, Respublika
Query!
Country [43]
0
0
Russian Federation
Query!
State/province [43]
0
0
Leningradskaya Oblast
Query!
Country [44]
0
0
Russian Federation
Query!
State/province [44]
0
0
Moskva
Query!
Country [45]
0
0
Russian Federation
Query!
State/province [45]
0
0
Sverdlovskaya Oblast
Query!
Country [46]
0
0
Russian Federation
Query!
State/province [46]
0
0
Sankt-Peterburg
Query!
Country [47]
0
0
Spain
Query!
State/province [47]
0
0
Asturias
Query!
Country [48]
0
0
Spain
Query!
State/province [48]
0
0
Cantabria
Query!
Country [49]
0
0
Spain
Query!
State/province [49]
0
0
Barcelona
Query!
Country [50]
0
0
Spain
Query!
State/province [50]
0
0
Madrid
Query!
Country [51]
0
0
Spain
Query!
State/province [51]
0
0
Sevilla
Query!
Country [52]
0
0
Taiwan
Query!
State/province [52]
0
0
Taichung
Query!
Country [53]
0
0
Taiwan
Query!
State/province [53]
0
0
Tainan
Query!
Country [54]
0
0
Taiwan
Query!
State/province [54]
0
0
Taipei
Query!
Country [55]
0
0
Taiwan
Query!
State/province [55]
0
0
Taoyuan
Query!
Country [56]
0
0
Turkey
Query!
State/province [56]
0
0
Ankara
Query!
Country [57]
0
0
Turkey
Query!
State/province [57]
0
0
Edirne
Query!
Country [58]
0
0
Turkey
Query!
State/province [58]
0
0
Istanbul
Query!
Country [59]
0
0
Turkey
Query!
State/province [59]
0
0
Izmir
Query!
Country [60]
0
0
Turkey
Query!
State/province [60]
0
0
Malatya
Query!
Country [61]
0
0
United Kingdom
Query!
State/province [61]
0
0
Cambridgeshire
Query!
Country [62]
0
0
United Kingdom
Query!
State/province [62]
0
0
Essex
Query!
Country [63]
0
0
United Kingdom
Query!
State/province [63]
0
0
London, City Of
Query!
Country [64]
0
0
United Kingdom
Query!
State/province [64]
0
0
Midlothian
Query!
Country [65]
0
0
United Kingdom
Query!
State/province [65]
0
0
Surrey
Query!
Country [66]
0
0
United Kingdom
Query!
State/province [66]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Merck Sharp & Dohme LLC
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Eisai Inc.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the safety and efficacy of lenvatinib (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in participants with metastatic colorectal cancer. The study will also compare lenvatinib plus pembrolizumab with the standard of care treatment of regorafenib and TAS-102 (trifluridine and tipiracil hydrochloride). The primary study hypothesis is that lenvatinib plus pembrolizumab is superior to standard of care with respect to overall survival.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04776148
Query!
Trial related presentations / publications
Kawazoe A, Xu RH, Garcia-Alfonso P, Passhak M, Teng HW, Shergill A, Gumus M, Qvortrup C, Stintzing S, Towns K, Kim TW, Shiu KK, Cundom J, Ananda S, Lebedinets A, Fu R, Jain R, Adelberg D, Heinemann V, Yoshino T, Elez E; LEAP-017 Investigators. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. J Clin Oncol. 2024 Jun 4:JCO2302736. doi: 10.1200/JCO.23.02736. Online ahead of print.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Merck Sharp & Dohme LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: http://engagezone.msd.com/ds_documentation.php
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
Study Protocol and Statistical Analysis Plan
https://cdn.clinicaltrials.gov/large-docs/48/NCT04776148/Prot_SAP_000.pdf
Statistical analysis plan
Study Protocol and Statistical Analysis Plan
https://cdn.clinicaltrials.gov/large-docs/48/NCT04776148/Prot_SAP_000.pdf
Results publications and other study-related documents
Type
Citations or Other Details
Journal
Kawazoe A, Xu RH, Garcia-Alfonso P, Passhak M, Ten...
[
More Details
]
Results not provided in
https://clinicaltrials.gov/study/NCT04776148